Allyx Therapeutics is focused on developing innovative treatments for neurodegenerative diseases by targeting the mGluR5 receptor, which plays a crucial role in neuronal communication and normal brain function. Their lead compound, ALX-001, is a first-in-class silent allosteric modulator that selectively inhibits the harmful activation of the mGluR5 receptor while preserving essential glutamate signaling necessary for cognitive function. This unique mechanism aims to halt the damaging effects of amyloid beta on synaptic networks, presenting a novel therapeutic approach for conditions such as Alzheimer’s disease and Parkinson’s disease. ALX-001 has demonstrated a wide therapeutic window, allowing for effective receptor binding without the on-target toxicity associated with other modulators.

The development of ALX-001 has progressed through various clinical studies, showcasing its safety and tolerability in patients with neurodegenerative disorders. The compound is orally bioavailable and capable of penetrating the brain, making it a promising candidate for treating these complex diseases. Allyx Therapeutics has secured an exclusive worldwide license for ALX-001 from Bristol Myers Squibb and Yale University, further solidifying its commitment to advancing research in this critical area of medicine. The company’s approach not only aims to protect synapses but also seeks to fundamentally change the treatment landscape for Alzheimer’s and other neurodegenerative diseases.

United States

Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer's and Parkinson's. They are developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease.

Allyx Therapeutics

Company Details